Literature DB >> 15928886

Preoperative embolization in spinal and pelvic metastases.

Reiner J Wirbel1, Reinhard Roth, Michael Schulte, Bernd Kramann, Wolf Mutschler.   

Abstract

The role of preoperative embolization should be evaluated for the surgical treatment of spinal and pelvic metastases. Selective embolization was performed in 32 patients (19 men, 13 women; mean age 63.4 years) before surgery by anterior resection of spinal metastases (n = 21) or pelvic metastases (n = 11). Evaluation parameters consisted of the intraoperative blood loss, the need for blood replacement, and the operating time. There was a significant difference in blood loss and transfusion requirements in the spinal group (P = 0.02) as well as in the pelvic group (P = 0.05) compared to a nonembolized control group of spinal (n = 20) and pelvic (n = 10) metastases. The operating time in the embolized group was shorter, but the difference was not significant. Surgical revision was required in two cases in the embolized spinal group owing to necrosis of the psoas muscle. No neurological deficit was observed that could be attributed to the embolization procedure. Preoperative embolization is thus a suitable method for reducing intraoperative blood loss and transfusion requirements in hypervascularized spinal and pelvic metastases.

Entities:  

Mesh:

Year:  2005        PMID: 15928886     DOI: 10.1007/s00776-005-0900-1

Source DB:  PubMed          Journal:  J Orthop Sci        ISSN: 0949-2658            Impact factor:   1.601


  24 in total

Review 1.  [Contrast-enhanced diagnostics in orthopaedics].

Authors:  D Proschek; M Mack; K Kafchitsas; G Fusshoeller; K Hochmuth
Journal:  Orthopade       Date:  2006-06       Impact factor: 1.087

2.  Embolisation of bone metastases from renal cancer.

Authors:  G Rossi; A F Mavrogenis; R Casadei; G Bianchi; C Romagnoli; E Rimondi; P Ruggieri
Journal:  Radiol Med       Date:  2012-03-19       Impact factor: 3.469

Review 3.  The evolution of pre-operative spine tumour embolization.

Authors:  Nima Omid-Fard; Charles G Fisher; Manraj Ks Heran
Journal:  Br J Radiol       Date:  2019-07-10       Impact factor: 3.039

4.  Not All Patients Undergoing Stabilization of Impending Pathologic Fractures for Renal Cell Carcinoma Metastases to the Femur Need Preoperative Embolization.

Authors:  Edward W Jernigan; Joshua N Tennant; Robert J Esther
Journal:  Clin Orthop Relat Res       Date:  2018-03       Impact factor: 4.176

5.  Preoperative embolization of primary bone tumors: A case control study.

Authors:  Roushan Jha; Raju Sharma; Shishir Rastogi; Shah Alam Khan; Arvind Jayaswal; Shivanand Gamanagatti
Journal:  World J Radiol       Date:  2016-04-28

6.  Embolization of musculoskeletal bone tumors.

Authors:  Richard J T Owen
Journal:  Semin Intervent Radiol       Date:  2010-06       Impact factor: 1.513

7.  Concomitant radiotherapy and transarterial chemoembolization reduce skeletal-related events related to bone metastases from renal cell carcinoma.

Authors:  Joichi Heianna; Wataru Makino; Takuro Ariga; Kazuki Ishikawa; Takeaki Kusada; Hitoshi Maemoto; Masafumi Toguchi; Junji Ito; Masato Goya; Minoru Miyazato; Yuko Iraha; Sadayuki Murayama
Journal:  Eur Radiol       Date:  2019-11-14       Impact factor: 5.315

8.  Embolization of hypervascular bone metastases reduces intraoperative blood loss: a case-control study.

Authors:  Theresa J C Pazionis; Ioannis D Papanastassiou; Majid Maybody; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2014-06-26       Impact factor: 4.176

9.  Retrospective analysis of preoperative embolization of spinal tumors.

Authors:  M A Wilson; D L Cooke; B Ghodke; S K Mirza
Journal:  AJNR Am J Neuroradiol       Date:  2009-11-26       Impact factor: 3.825

10.  Transarterial chemoembolization for pain relief in patients with hypervascular painful metastatic spinal tumors refractory to percutaneous vertebroplasty.

Authors:  Yi Chen; Zhiping Yan; Jianhua Wang; Xiaolin Wang; Jiemin Cheng; Gaoquan Gong; Jianjun Luo
Journal:  J Cancer Res Clin Oncol       Date:  2013-05-16       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.